Inotek Pharmaceuticals, a US-based pharmaceutical company which is developing products to treat glaucoma, has raised $21m financing. All of the company’s existing investors participated in the financing, including MedImmune Ventures, the biologics research and development arm of Anglo-Swedish pharmaceuticals company AstraZeneca, and venture capital funds Devon Park Bioventures, Rho Ventures, Care Capital and Pitango Venture Capital.

Proceeds from this financing will be used to advance Inotek’s lead product, trabodenoson, an eye drop ,through phase 2…